Tokyo, Sept. 29 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059191) titled 'A Multicenter Prospective Observational Study of Dysphagia and Dysphonia in Interstitial Lung Disease: R6-EBM(Kokyu)-01' on Sept. 29.
Study Type:
Observational
Primary Sponsor:
Institute - NHO Kinki Chuo Chest Medical Center
Condition:
Condition - Interstitial lung disease: ILD, including Idiopathic pleuroparenchymal fibroelastosis: IPPFE and Idiopathic pulmonary fibrosis: IPF
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To clarify the prevalence, clinical features, and prognostic impact of dysphagia and dysphonia in ILD through a prospective observational study
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Diagnosis of IPPFE or IPF: Eligible participants include those diagnosed with IPPFE or IPF, as determined by the attending physician at each participating institution. In cases of combined disease, classification should be based on the predominant radiological and/or clinical features of either IPPFE or IPF.
Key exclusion criteria - Patients meeting any of the following conditions are excluded from the study:
A confirmed diagnosis of collagen vascular disease, hypersensitivity pneumonitis, pneumoconiosis, or drug induced interstitial lung disease.
Active or Preceding Pulmonary Infections
Post Transplant Status
Poor General Condition: Patients with an ECOG Performance Status of 4.
Limited Life Expectancy: Patients with an estimated life expectancy of less than 3 months due to non ILD related comorbidities or complications.
Advanced Malignancy: Patients with incurable advanced stage malignancy.
Impaired Consciousness: Patients with a decreased level of consciousness worse than Japan Coma Scale I2.
Oropharyngeal Structural Disease: Patients with known head and neck diseases that may independently cause swallowing dysfunction.
Neurological Sequelae of Stroke: Patients with post ischemic cerebral infarction presenting with obvious motor paralysis or swallowing dysfunction attributed to the stroke.
Neurodegenerative Disorders: Patients with dementia or Parkinsons disease when associated with swallowing dysfunction.
Neuromuscular Disorders: Patients diagnosed with neuromuscular diseases such as amyotrophic lateral sclerosis, myasthenia gravis, or polymyositis.
Use of Certain Medications: Patients who are regularly taking antipsychotic medications or anticonvulsants.
Investigators Discretion: Patients deemed unsuitable for participation by the Principal Investigator or site Research Supervisor for any reason.
Target Size - 300
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2025 Year 04 Month 10 Day
Date of IRB - 2025 Year 02 Month 21 Day
Anticipated trial start date - 2025 Year 05 Month 23 Day
Last follow-up date - 2031 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066098
Disclaimer: Curated by HT Syndication.